Zura Bio Ltd

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q4 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zura Bio Ltd. is a clinical-stage biotechnology company that engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV.

HENDERSON, Nev--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights. The Company has also announced the appointment of Robert Lisicki as Chief Executive Officer (CEO), effective April 8, 2024, succeeding its Founding CEO, Someit Sidhu, M.D. Dr. Sidhu will continue to serve Zura Bio as a non.

Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio announces participation at three March conferences.

Zura Bio Announces Participation at March Conferences

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio today announced participation at several upcoming conferences in February.

Zura Bio Announces Participation at February Investor Conferences

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Announces Appointment of Robert Lisicki as President and Dr. Kiran Nistala as CMO.

Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit.

Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio announces two immunology abstracts presented at World Allergy Congress (WAC) for ZB-168 and ZB-880.

Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) announced Arnout Ploos van Amstel has been appointed to its Board of Directors.

Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights. "In the third quarter, Zura Bio made significant progress in its strategic planning across various key areas, including Clinical, Regulatory, CMC, and Translational Science. This p.

Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, and Benaroya Research Institute (BRI), a Seattle based non-profit research institute within Virginia Mason Franciscan Health, announced that they have entered into a sponsored research agreement focused on further characterizing the pivotal role of Interleukin-7 receptor alpha (IL-7Rα) in T.

Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the second quarter ended June 30, 2023, and recent business highlights. “Zura Bio made great progress in the first half of 2023, and we look forward to advancing our multi-asset pipeline which includes our lead asset, ZB-106, also k.

Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights

SAN DIEGO--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio will be added to the Russell 2000® and Russell 3000® Indexes effective after the US market opens on June 26, 2023.

Zura Bio to Join the Russell 2000® and Russell 3000® Indexes

Zura Bio's lead therapy is ZB-106. The company plans to start two phase 2 trials for the therapy.

Why Shares of Zura Bio Climbed Tuesday

Zura Bio (NASDAQ: ZURA ) stock is on the rise Tuesday alongside a couple of positive pieces of news from the clinical-stage biotechnology company. First off, investors will note that Zura Bio completed a private placement that saw it raise $80 million.

Why Is Zura Bio (ZURA) Stock Up 9% Today?

SAN DIEGO--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: “ZURA”) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the final closing of a private placement resulting in gross proceeds to Zura Bio of approximately $80 million. This funding will allow Zura Bio to initiate a Phase 2 clinical trial for ZB-106 in systemic sclerosis (SSc), followed by a Phase 2 clinical trial in hidradenitis suppu.

Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist

SAN DIEGO--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: “ZURA”) (“Zura” or “Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the license from Eli Lilly and Company (“Lilly”) of tibulizumab, a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist. Following the closing, the compound will be known as ZB-106. ZB-106 currently has clinical data from two Phase 1b studies completed in.

Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases

SAN DIEGO--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited announces the appointment of Michael D. Howell, Ph.D., to the role of Chief Scientific Officer and Head of Translational Science.

Zura Bio Announces Appointment of Chief Scientific Officer

Zura Bio (NASDAQ: ZURA ) stock is on the move Thursday following the clinical-stage biotechnology company's recent public debut. Zura Bio went public on Tuesday after completing its special purpose acquisition company (SPAC) merger with JATT Acquisition Corp. Afterward, the company's shares saw a massive spike in price during trading on Wednesday.

ZURA Stock Alert: Zura Bio SPAC Merger Rally Ends

One of today's biggest market sensations is Zura Bio Limited (NASDAQ: ZURA ). The clinical-stage biotechnology firm recently completed a merger with JATT Acquisition Corp, a special-purpose acquisition company (SPAC).

ZURA Stock Alert: Low-Float Zura Bio Rockets 300%

Jatt Acquisition Corp

SAN DIEGO--(BUSINESS WIRE)--Zura Bio Limited (“Zura”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the closing of its business combination with JATT Acquisition Corp, a special purpose acquisition company (NYSE: JATT) (“JATT”), on March 20, 2023. The business combination was approved on March 16, 2023 by JATT's shareholders.

Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp

LONDON--(BUSINESS WIRE)--JATT Acquisition Corp (NYSE: JATT) (“JATT”), a publicly traded special purpose acquisition company, today announced that its shareholders voted to approve its proposed business combination with Zura Bio Limited (“Zura”), a clinical-stage biotechnology company. At the extraordinary general meeting of JATT's shareholders, a total of 4,907,863 ordinary shares, or 95.

News for Zura Bio Ltd Stock (ZURA)